Protagonist Therapeutics Inc

PTGXNASDAQ · USD
141.86USD0.00 (+3.30%)
6610

Protagonist Therapeutics Inc (PTGX) Wheel Strategy

PTGX wheel strategy scan found 21 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 65.7%.

Read more

Running a PTGX wheel strategy lets you generate consistent premium income on Protagonist Therapeutics Inc while setting your own entry and exit prices on the underlying. Protagonist Therapeutics Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own PTGX, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best PTGX wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on PTGX, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable PTGX wheel from a losing one.

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.

The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the PTGX wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your PTGX wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.

Oct 16, 2026135.00$3.20$5.35-0.412236%54.5%65.7%11
Oct 16, 2026125.00$0.90$2.90-0.232236%78.4%38.5%26
Nov 20, 2026135.00$5.70$8.10-0.415736%51.3%38.4%0
Oct 16, 2026130.00$0.65$2.73-0.282236%67.1%34.8%20
Nov 20, 2026130.00$3.50$5.90-0.335736%59.4%29.1%0
Jan 15, 2027130.00$7.20$8.85-0.3411336%55.0%22.0%2
Nov 20, 2026125.00$1.85$4.18-0.265736%67.3%21.4%1
Jan 15, 2027125.00$4.30$6.35-0.2811336%60.9%16.4%6
Apr 16, 2027130.00$9.20$11.60-0.3420436%51.8%16.0%0
Nov 20, 2026120.00$0.50$2.75-0.195736%74.8%14.7%0

As of September 25, 2026

Run the Wheel on PTGX With Confidence

Find the best PTGX wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.

Start your 14-day free trial